Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Not applicable

Maxillary Sinus Augmentation Using CAD/CAM Allogenic Bone Blocks Versus Particulate Allogenic Grafts

NCT07604155 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-09-03
Last updated
2026-05-22

Condition(s) studied

Maxillary SinusAllograft

Investigational drug(s) / intervention(s)

sinus lifting using CAD/CAM allogenic blocksinus lifting using particulate allogenic graft

sinus lifting using CAD/CAM allogenic block: A full-thickness, wide mucoperiosteal flap was elevated buccally. A lateral bony window of the maxillary sinus will be made, then the sinus lining will be carefully elevated. The CAD/CAM allogenic block will be inserted and fixed in its position via a titanium screw to the crest of maxillary ridge (group I). • The lateral window will be covered with collagen membrane, the flap will be repositioned in its place and sutured.

sinus lifting using particulate allogenic graft: In group II the particulate bone will packed at the site of augmentation

Study summary

28 patients will be included in this study with atrophic posterior maxillary ridge due to sinus pneumatization who will randomly assigned to two groups

* Group I: sinus lifting using CAD/CAM allogenic block through lateral window technique
* Group II: sinus lifting using particulate allogenic graftthrough lateral window technique

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * above 20 years * ridge height less than or equal to 5 mm * healthy clear sinus Exclusion Criteria: * systemic disease affect bone healing * heavy smokers * disease or pathology within the sinus

Primary outcome measure(s)

  • bone height gain — 6 months
    using CBCT
  • marginal bone resorption around implants — 6 months
    CBCT

Trial sites (1)

FacilityCityRegionStatus
Faculty of Dentistry, Tanta University Tanta Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07604155 on ClinicalTrials.gov ↗ ← All trials in Egypt